30 closest matches · ranked by relevance
LQT2 Syndrome
Primary: Change From Baseline in Standard 12-Lead Electrocardiogram (ECG) Daytime QT Interval Corrected For Heart Rate Using The Fridericia Formula (QTcF) (AUC0-8)/8 at Day 3…
Long QT Syndrome · Sleep Apnea
Primary: QT Interval (Corrected) Baseline Visit — 453.4 square root of seconds — p=0.73
Long QT Syndrome
Primary: Change in QTc Duration at 2 Months — 503; 497 miliseconds — p=0.7958
Jervell and Lange Nielsen Syndrome
Primary: QT Interval — 623 ms
Long QT Syndrome · Cardiac Repolarization
Primary: QTc Response to Exercise on Versus Off Beta-blocker. — 320; 317; 317; 315 ms
Atrial Arrhythmia · QT Interval, Variation in · Arrhythmias, Cardiac
Primary: QT Intervals During Antiarrhythmic Loading Hospitalization — 21.8 milliseconds
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change in Placebo Corrected Change From Baseline QTc and J-Tpeakc Intervals on the ECG Measured in Milliseconds When Dofetilide is Administered With Mexiletine or…
Long QT Syndrome
Primary: Baseline (Pre-ibutilide) Individualized Rate-corrected QT Interval (QTF) — 393; 399; 399 ms — p=0.09
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir) — -8.3; -7.8; -11.5; -10.9 ms
Prolonged QT Interval in EKG and Sudden Death
Primary: Baseline (Pre-Ibutilide) QTcI Intervals — 412; 419 ms — p=0.04
Healthy Volunteers
Primary: Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 4.04 msec
Thorough QT/QTc Study
Primary: Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.418 mseconds
Metastatic Breast Cancer
Primary: Change From Baseline in Mean Duration of the QTc Interval — 1.2; -1.0; -4.0; -0.1 milliseconds
Cardiotoxicity
Primary: Maximum Effect of Inhaled Prochlorperazine on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.493; 5.229 milliseconds
Long QT Syndrome · Abnormalities, Drug-Induced
Primary: Baseline (Pre-ibutilide) QT-F Intervals — 417; 421; 413; 414 ms — p=0.07
Diabetes Related Complications
Primary: Change in the Corrected QT-interval During Nocturnal Hypoglycemia — 3; 5 Participants
Drug-induced Surface ECG Changes
Primary: Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc — 6.5; 2.3; 32.1; 5.1 ms — p=<0.05
Healthy
Primary: Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib — -1.62; -2.28 milliseconds
Healthy
Primary: Change From Baseline in QTcF at That Timepoint Between 20 Minutes to 24 Hours After Drug Administration Where the Difference of Means in QTcF Changes From Baseline…
Advanced Solid Tumors
Primary: Mean Change From Time-Matched Baseline in QTcI, Individual Baseline Corrected Rate-Corrected QT Interval — -1.3; -7.7; -1.1; -2.0 msec
Heart Disease
Primary: For the Primary Endpoint the Reduction of Ventricular Therapies (ATP and Shocks) Delivered for Treating Fast Spontaneous Arrhythmia Episodes Was Measured. — 67.1; 41.9…
Solid Tumors
Primary: Change in QTcF (QT Corrected According to Fridericia's Formula) — 3.32; 1.76; 1.84; 1.32 ms (Milliseconds)
Advanced Solid Tumor
Primary: Mean Time-matched, Baseline Corrected QTcF at Any Time Point Postdosing. — 2; 11 msec
Healthy
Primary: Cardiodynamics: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) for Treatments A, B, and C — 3.4; 4.4; 6.4…
Duchenne and Becker Muscular Dystrophy · Polycytemia Vera
Primary: Placebo-corrected Change From Baseline in Fridericia's Corrected QT Interval (QTcF) — 1.0; 0.5; 10.2; 0.3 Milliseconds (msec)
Healthy
Primary: Setmelanotide Concentration-related Placebo-corrected Change From Baseline (CHFB) in Fridericia's Correction (QTcF) at Day 10 — 1.9; -1.5; -3.6; -3.5 milliseconds (msec)
Heart Failure
Primary: Freedom From Left Ventricular Lead-Related Complications Through 3 Months — 96 percentage probability
Healthy Volunteers
Primary: Change From Baseline to Day 10 in QT Interval Corrected for Heart Rate (QTc) for LY2484595 Versus Placebo — -2.7; -4.6; -2.0; -1.1 milliseconds (msec)
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
Healthy
Primary: Maximal Mean ΔΔQTcF — 5.0; 23.4; 0.8; 12.3 milliseconds